US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
AU1583397A
(en)
|
1996-01-30 |
1997-08-22 |
Brigham And Women's Hospital |
Antibodies for modulating cd47-mediated neutrophil transmigration
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
CA2226962A1
(en)
|
1998-02-16 |
1999-08-16 |
Marie Sarfati |
Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
|
AU1701001A
(en)
|
1999-11-30 |
2001-06-12 |
Eberhard-Karls-Universitat Tubingen Universitatsklinikum |
Antibodies against signal regulator proteins
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
AU2002315052A1
(en)
|
2001-05-15 |
2002-11-25 |
Emory University |
Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US7841940B2
(en)
|
2003-07-14 |
2010-11-30 |
Astav, Inc |
Human test based on human conceptual capabilities
|
CA2545166A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
CN101031569B
(zh)
|
2004-05-13 |
2011-06-22 |
艾科斯有限公司 |
作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US7442716B2
(en)
|
2004-12-17 |
2008-10-28 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
|
EP1828143B1
(en)
|
2004-12-17 |
2013-03-20 |
Merck Frosst Canada Ltd. |
2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
CN101223170A
(zh)
|
2005-05-18 |
2008-07-16 |
惠氏公司 |
Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法
|
CN101223143A
(zh)
|
2005-05-18 |
2008-07-16 |
惠氏公司 |
作为tpl2激酶抑制剂的3-氰基喹啉以及其制备和应用方法
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
TW201402124A
(zh)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
WO2007124589A1
(en)
|
2006-05-02 |
2007-11-08 |
Merck Frosst Canada Ltd. |
Methods for treating or preventing neoplasias
|
EP2027151A2
(en)
|
2006-05-15 |
2009-02-25 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
BRPI0711901A2
(pt)
|
2006-05-22 |
2012-03-06 |
The Regents Of The University Of California |
Composições e métodos para a liberação de oxigênio
|
ITMI20061053A1
(it)
|
2006-05-30 |
2007-11-30 |
Manuli Rubber Ind Spa |
Raccordo per tubi flessibili per applicazioni oleodinamiche,industriali e aria condizionata,avente caratteristiche di tenuta migliorate.
|
DE102006058450A1
(de)
|
2006-12-12 |
2008-06-19 |
Eberhard-Karls-Universität Tübingen |
Zubereitungen zur Hemmung der Prostaglandin E2 Synthese
|
EP2170888B1
(en)
|
2007-06-29 |
2015-04-22 |
Gilead Sciences, Inc. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
CA2702217A1
(en)
|
2007-10-11 |
2009-04-16 |
Jayne Danska |
Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
|
TW200930369A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
TW200930368A
(en)
|
2007-11-15 |
2009-07-16 |
Astrazeneca Ab |
Bis-(sulfonylamino) derivatives in therapy
|
US20090163586A1
(en)
|
2007-12-20 |
2009-06-25 |
Astrazeneca Ab |
Bis-(Sulfonylamino) Derivatives in Therapy 205
|
WO2009103778A1
(en)
|
2008-02-19 |
2009-08-27 |
Novasaid Ab |
Compounds and methods
|
WO2009117987A2
(de)
|
2008-03-26 |
2009-10-01 |
Universität Tübingen |
Verwendung von boswelliasäuren und synthetischen boswelliasäurederivaten zur hemmung der mikrosomalen prostaglandin e2 synthase und des cathepsin g
|
WO2009130242A1
(en)
|
2008-04-23 |
2009-10-29 |
Novasaid Ab |
Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
|
EP2119705A1
(en)
|
2008-05-14 |
2009-11-18 |
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. |
3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
|
DE102008027331A1
(de)
|
2008-06-07 |
2009-12-10 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
|
DE102008015432A1
(de)
|
2008-06-12 |
2009-12-17 |
Eberhard-Karls-Universität Tübingen |
Verwendung von Pirinixinsäure-Derivaten zur Hemmung der Prostaglandin E2 Synthese
|
US8242106B2
(en)
|
2008-08-01 |
2012-08-14 |
Ventirx Pharmaceuticals, Inc. |
Toll-like receptor agonist formulations and their use
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
UY32138A
(es)
|
2008-09-25 |
2010-04-30 |
Boehringer Ingelheim Int |
Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
KR101687841B1
(ko)
|
2008-12-09 |
2016-12-19 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체의 조절제
|
EA201100947A1
(ru)
|
2008-12-19 |
2012-02-28 |
Новартис Аг |
Растворимые полипептиды, предназначенные для применения при лечении аутоиммунных и воспалительных нарушений
|
WO2010083253A2
(en)
|
2009-01-14 |
2010-07-22 |
Viral Logic Systems Technology Corp. |
Cd47 related compositions and methods for treating immunological diseases and disorders
|
UY32470A
(es)
|
2009-03-05 |
2010-10-29 |
Boehringer Ingelheim Int |
Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
|
TWI491606B
(zh)
|
2009-07-13 |
2015-07-11 |
Gilead Sciences Inc |
調節細胞凋亡信號之激酶的抑制劑
|
US8524702B2
(en)
|
2009-08-18 |
2013-09-03 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
CN102753542B
(zh)
|
2009-08-18 |
2016-01-20 |
文蒂雷克斯药品公司 |
作为t0ll样受体调节剂的取代的苯并氮杂*
|
WO2011023812A1
(en)
|
2009-08-27 |
2011-03-03 |
Novasaid Ab |
Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
|
KR101793300B1
(ko)
|
2009-10-22 |
2017-11-02 |
길리애드 사이언시즈, 인코포레이티드 |
특히 바이러스성 감염의 치료에 유용한 퓨린 또는 데아자퓨린의 유도체
|
JP5579862B2
(ja)
|
2009-10-23 |
2014-08-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター
|
EP2516458A1
(en)
|
2009-12-22 |
2012-10-31 |
Novartis AG |
Tetravalent cd47-antibody constant region fusion protein for use in therapy
|
DK2569013T3
(da)
|
2010-05-14 |
2017-02-13 |
Univ Leland Stanford Junior |
Humaniserede og kimære monoklonale antistoffer til cd47
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
US8759537B2
(en)
|
2010-08-20 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
|
US8586604B2
(en)
|
2010-08-20 |
2013-11-19 |
Boehringer Ingelheim International Gmbh |
Inhibitors of the microsomal prostaglandin E2 synthase-1
|
JP5878538B2
(ja)
|
2010-08-27 |
2016-03-08 |
ギリアド バイオロジクス, インク.Gilead Biologics, Inc. |
マトリクスメタロプロティナーゼ9に対する抗体
|
WO2012045089A2
(en)
|
2010-10-01 |
2012-04-05 |
Ventirx Pharmaceuticals, Inc. |
Methods for the treatment of allergic diseases
|
ES2616449T3
(es)
|
2010-10-01 |
2017-06-13 |
Ventirx Pharmaceuticals, Inc. |
Uso terapéutico de un agonista de TLR y terapia de combinación
|
BR122021026169B1
(pt)
|
2010-12-09 |
2023-12-12 |
The Trustees Of The University Of Pennsylvania |
Uso de uma célula
|
UY33779A
(es)
|
2010-12-10 |
2012-07-31 |
Boehringer Ingelheim Int |
?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
|
US8466186B2
(en)
|
2010-12-10 |
2013-06-18 |
Boehringer Ingelheim International Gmbh |
Compounds
|
US9096532B2
(en)
|
2010-12-13 |
2015-08-04 |
The Regents Of The University Of California |
Pyrazole inhibitors of COX-2 and sEH
|
AR084174A1
(es)
|
2010-12-21 |
2013-04-24 |
Lilly Co Eli |
Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
|
BR112013017943A2
(pt)
|
2011-01-12 |
2018-12-18 |
Array Biopharma Inc |
benzoazepinas substituídas como moduladores receptores do tipo toll
|
MX348935B
(es)
|
2011-01-12 |
2017-07-03 |
Ventirx Pharmaceuticals Inc |
Benzoazepinas sustituidas como moduladores de receptores tipo toll.
|
WO2012110860A1
(en)
|
2011-02-17 |
2012-08-23 |
Glenmark Pharmaceuticals S.A. |
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
ME03782B
(me)
|
2011-04-08 |
2021-04-20 |
Janssen Sciences Ireland Unlimited Co |
Derivati pirimidina za tretman virusnih infekcija
|
EA028254B1
(ru)
|
2011-05-18 |
2017-10-31 |
Янссен Сайенсиз Айрлэнд Юси |
Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
|
AR086254A1
(es)
|
2011-05-26 |
2013-11-27 |
Lilly Co Eli |
Derivados de imidazol utiles para el tratamiento de artritis
|
WO2012170250A1
(en)
|
2011-06-07 |
2012-12-13 |
Radiation Control Technologies, Inc. |
Morpholino oligonucleotides capable of inhibiting cd47-mediated cellular damage and uses thereof
|
MY166866A
(en)
|
2011-08-18 |
2018-07-24 |
Nippon Shinyaku Co Ltd |
Heterocyclic derivative and pharmaceutical drug
|
EP2749572A4
(en)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
US20140235643A1
(en)
|
2011-10-04 |
2014-08-21 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
US20140242095A1
(en)
|
2011-10-19 |
2014-08-28 |
University Health Network |
Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
|
WO2013072825A1
(en)
|
2011-11-16 |
2013-05-23 |
Glenmark Pharmaceuticals S.A. |
Phtalazinone derivatives as mpegs -1 inhibitors
|
CA2857344C
(en)
|
2011-12-21 |
2019-02-12 |
Novira Therapeutics, Inc. |
Hepatitis b antiviral agents
|
PL2804617T3
(pl)
|
2012-01-17 |
2020-11-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Reagenty sirp-alfa o wysokim powinowactwie
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
US20140140989A1
(en)
|
2012-02-06 |
2014-05-22 |
Inhibrx Llc |
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
|
HUE13746964T2
(hu)
|
2012-02-06 |
2020-01-28 |
Inhibrx Inc |
CD47 antitestek és alkalmazási eljárásaik
|
IN2014MN01736A
(he)
|
2012-02-08 |
2015-07-10 |
Janssen R & D Ireland |
|
AR089939A1
(es)
|
2012-02-09 |
2014-10-01 |
Glenmark Pharmaceuticals Sa |
COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1
|
WO2013153535A1
(en)
|
2012-04-13 |
2013-10-17 |
Glenmark Pharmaceuticals S.A. |
TRICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
TWI568722B
(zh)
|
2012-06-15 |
2017-02-01 |
葛蘭馬克製藥公司 |
作爲mPGES-1抑制劑之三唑酮化合物
|
IN2015MN00478A
(he)
|
2012-08-10 |
2015-09-04 |
Janssen Sciences Ireland Uc |
|
WO2014047624A1
(en)
|
2012-09-24 |
2014-03-27 |
Gilead Sciences, Inc. |
Anti-ddr1 antibodies
|
CN104837840B
(zh)
|
2012-10-10 |
2017-08-08 |
爱尔兰詹森科学公司 |
用于治疗病毒感染及其他疾病的吡咯并[3,2‑d]嘧啶衍生物
|
WO2014064215A1
(en)
|
2012-10-24 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
|
AU2013346793B2
(en)
|
2012-11-16 |
2018-03-08 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
ES2784631T3
(es)
|
2012-12-03 |
2020-09-29 |
Novimmune Sa |
Anticuerpos anti-CD47 y métodos de uso de los mismos
|
WO2014093678A2
(en)
|
2012-12-12 |
2014-06-19 |
Frazier William A |
Therapeutic cd47 antibodies
|
DK2931752T3
(da)
|
2012-12-17 |
2019-11-18 |
Trillium Therapeutics Inc |
Behandling af cd47+ sygdomsceller med sirp-alpha-fc-fusioner
|
NZ708864A
(en)
|
2012-12-21 |
2016-09-30 |
Gilead Calistoga Llc |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
US9029384B2
(en)
|
2012-12-21 |
2015-05-12 |
Gilead Calistoga, LLC. |
Phosphatidylinositol 3-kinase inhibitors
|
CA2897018C
(en)
|
2013-01-07 |
2021-07-27 |
Omniox, Inc. |
Polymeric forms of h-nox proteins
|
KR102300861B1
(ko)
|
2013-02-21 |
2021-09-10 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
CA2903773A1
(en)
*
|
2013-03-15 |
2014-09-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for achieving therapeutically effective doses of anti-cd47 agents
|
WO2014167444A1
(en)
|
2013-04-08 |
2014-10-16 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
|
WO2014201409A1
(en)
|
2013-06-14 |
2014-12-18 |
Gilead Sciences, Inc. |
Phosphatidylinositol 3-kinase inhibitors
|
WO2015059618A1
(en)
|
2013-10-22 |
2015-04-30 |
Glenmark Pharmaceuticals S.A. |
SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
WO2015138600A2
(en)
|
2014-03-11 |
2015-09-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
|
BR112016021641A2
(pt)
|
2014-03-27 |
2017-08-15 |
Eicosis Llc |
Potentes inibidores da epóxido hidrolase solúveis
|
JP6788573B6
(ja)
|
2014-04-10 |
2020-12-16 |
シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
メトトレキサートによる選択と組み合わせたSleeping Beautyトランスポゾンによる遺伝子改変T細胞の製造
|
AU2015246577B2
(en)
|
2014-04-14 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof
|
TWI759810B
(zh)
|
2014-08-08 |
2022-04-01 |
美商Alx腫瘤技術股份有限公司 |
信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
|
US10087257B2
(en)
|
2014-08-08 |
2018-10-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRP alpha-antibody fusion proteins
|
ES2751915T5
(es)
|
2014-08-15 |
2022-12-23 |
Merck Patent Gmbh |
Proteínas de fusión de inmunoglobulina con SIRP alfa
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
AR102361A1
(es)
|
2014-10-29 |
2017-02-22 |
Lilly Co Eli |
Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2
|
JO3581B1
(ar)
|
2014-10-29 |
2020-07-05 |
Lilly Co Eli |
مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي
|
SG11201704058TA
(en)
|
2014-11-18 |
2017-06-29 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
JP7068820B2
(ja)
|
2014-12-03 |
2022-05-17 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法のための方法および組成物
|
US20160158360A1
(en)
|
2014-12-05 |
2016-06-09 |
Genentech, Inc. |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
CA2966234A1
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
WO2016109415A1
(en)
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
JP6643350B2
(ja)
|
2015-03-04 |
2020-02-12 |
ソレント・セラピューティクス・インコーポレイテッド |
Cd47に結合する抗体医薬
|
CN107580499A
(zh)
|
2015-03-17 |
2018-01-12 |
欧姆尼奥克斯公司 |
通过蛋白质介导的o2递送调节肿瘤免疫性
|
US10358472B2
(en)
|
2015-05-06 |
2019-07-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
High affinity CD47 analogs
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
CN104804093A
(zh)
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
MA43344A
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
WO2016205042A1
(en)
|
2015-06-16 |
2016-12-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
SIRPα AGONIST ANTIBODY
|
PL3322711T3
(pl)
|
2015-06-25 |
2021-10-25 |
University Health Network |
Inhibitory hpk1 i sposoby ich zastosowania
|
CN108350048B
(zh)
|
2015-08-07 |
2024-02-09 |
Alx肿瘤生物技术公司 |
具有SIRP-α结构域或其变体的构建体
|
AU2016323985B2
(en)
|
2015-09-17 |
2022-12-15 |
Novartis Ag |
CAR T cell therapies with enhanced efficacy
|
AU2016324316B2
(en)
|
2015-09-18 |
2023-02-09 |
Arch Oncology, Inc. |
Therapeutic CD47 antibodies
|
CN108290948B
(zh)
|
2015-09-21 |
2021-10-29 |
伊拉兹马斯大学医疗中心 |
抗-cd47抗体及使用方法
|
MA43389A
(fr)
|
2015-12-02 |
2021-05-12 |
Agenus Inc |
Anticorps anti-ox40 et leurs procédés d'utilisation
|
WO2017096276A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Anti-gitr antibodies and methods of use thereof
|
JP7089470B2
(ja)
|
2015-12-02 |
2022-06-22 |
アジェナス インコーポレイテッド |
抗体およびその使用方法
|
EP3383431A4
(en)
|
2015-12-02 |
2019-08-28 |
Agenus Inc. |
ANTI-GITR ANTIBODIES AND METHOD OF USE THEREOF
|
AU2016364891A1
(en)
|
2015-12-03 |
2018-06-07 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
EP3389695A4
(en)
|
2015-12-16 |
2019-10-09 |
The Walter and Eliza Hall Institute of Medical Research |
INHIBITION OF SH2 PROTEINS INDUCED BY CYTOKINES IN NK CELLS
|
CN114716552B
(zh)
|
2016-01-11 |
2024-05-24 |
四十七公司 |
人源化、小鼠或嵌合抗cd47单克隆抗体
|
WO2017147410A1
(en)
|
2016-02-25 |
2017-08-31 |
Amgen Inc. |
Compounds that inhibit mcl-1 protein
|
US10858338B2
(en)
|
2016-03-15 |
2020-12-08 |
The Regents Of The University Of California |
Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)
|
UA126658C2
(uk)
|
2016-04-14 |
2023-01-11 |
Осе Іммьюнотерапьютікс |
НОВІ АНТИТІЛА ДО SIRPa ТА ВАРІАНТИ ЇХ ТЕРАПЕВТИЧНОГО ЗАСТОСУВАННЯ
|
SG11201808465UA
(en)
|
2016-04-14 |
2018-10-30 |
Ose Immunotherapeutics |
NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
|
US20190091290A1
(en)
|
2016-04-15 |
2019-03-28 |
Trillium Therapeutics Inc. |
Macrophage stimulation in cd47 blockade therapy
|
US20200255515A1
(en)
|
2016-05-09 |
2020-08-13 |
Celgene Corporation |
Cd47 antibodies and methods of use thereof
|
EP3243522A1
(en)
|
2016-05-10 |
2017-11-15 |
Université Pierre et Marie Curie (Paris 6) |
Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
|
CA3026784A1
(en)
|
2016-06-07 |
2017-12-14 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic pyrazine derivatives useful as shp2 inhibitors
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
ES2800339T3
(es)
|
2016-06-30 |
2020-12-29 |
Gilead Sciences Inc |
4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
|
EP3493845A4
(en)
|
2016-08-03 |
2020-04-15 |
The Board of Trustees of the Leland Stanford Junior University |
INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
|
US10280164B2
(en)
|
2016-09-09 |
2019-05-07 |
Incyte Corporation |
Pyrazolopyridone compounds and uses thereof
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
CN109923114B
(zh)
|
2016-09-09 |
2022-11-01 |
因赛特公司 |
作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
|
CA3036384A1
(en)
|
2016-09-14 |
2018-03-22 |
Gilead Sciences, Inc. |
Syk inhibitors
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
US20200140565A1
(en)
|
2016-10-20 |
2020-05-07 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
EP3529276A4
(en)
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
US11352425B2
(en)
|
2016-11-08 |
2022-06-07 |
Absos, Llc |
Anti-CD47 antibodies
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
|
TW201819413A
(zh)
|
2016-11-28 |
2018-06-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Cd47抗體、其抗原結合片段及其醫藥用途
|
JP7025426B2
(ja)
|
2016-11-30 |
2022-02-24 |
アリアド ファーマシューティカルズ, インコーポレイテッド |
造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas
|
SG10201912879YA
(en)
|
2016-12-09 |
2020-02-27 |
Alector Llc |
Anti-sirp-alpha antibodies and methods of use thereof
|
EP3574009A4
(en)
|
2017-01-26 |
2020-11-25 |
Zlip Holding Limited |
CD47 ANTIGEN BINDING UNIT AND ITS USES
|
JP7132937B2
(ja)
|
2017-03-15 |
2022-09-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hpk1の阻害剤としてのアザインドール
|
KR20210130254A
(ko)
|
2017-03-23 |
2021-10-29 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
TW201843139A
(zh)
|
2017-03-30 |
2018-12-16 |
瑞士商赫孚孟拉羅股份公司 |
作為hpk1之抑制劑的異喹啉
|
WO2018183956A1
(en)
|
2017-03-30 |
2018-10-04 |
Genentech, Inc. |
Naphthyridines as inhibitors of hpk1
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Mcl−1タンパク質を阻害する化合物
|
EP3609922A2
(en)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
AU2018268304A1
(en)
|
2017-05-16 |
2019-11-14 |
Byondis B.V. |
Anti-SIRPα antibodies
|
CN109096395B
(zh)
|
2017-06-20 |
2022-06-24 |
华兰生物工程股份有限公司 |
阻断型cd47纳米抗体及其用途
|
AU2018290248A1
(en)
*
|
2017-06-21 |
2019-11-28 |
Forty Seven, Inc. |
Dosing parameters for CD47 targeting therapies to hematologic malignancies
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
US11401329B2
(en)
|
2017-08-02 |
2022-08-02 |
Phanes Therapeutics, Inc. |
Anti-CD47 antibodies and uses thereof
|
BR112020003306A2
(pt)
|
2017-08-18 |
2020-08-25 |
Ultrahuman Four Limited |
agentes de ligação
|
CN109422811A
(zh)
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN108503708B
(zh)
|
2017-09-01 |
2021-07-30 |
北京智仁美博生物科技有限公司 |
抗人cd47抗体及其用途
|
CN109422726B
(zh)
|
2017-09-04 |
2022-10-28 |
华东理工大学 |
CD47/SIRPα的阻断剂及其应用
|
AU2018358004A1
(en)
|
2017-11-01 |
2020-05-28 |
Hummingbird Bioscience Pte. Ltd. |
CD47 antigen-binding molecules
|
WO2019103203A1
(ko)
|
2017-11-24 |
2019-05-31 |
주식회사 젬백스앤카엘 |
신규 펩티드 및 이를 포함한 조성물
|
US11180552B2
(en)
|
2017-12-01 |
2021-11-23 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
KR20200108846A
(ko)
|
2018-01-12 |
2020-09-21 |
오리진 디스커버리 테크놀로지스 리미티드 |
Cd47 신호전달 경로의 저해제로서의 1,2,4-옥사다이아졸 화합물
|
US20210070855A1
(en)
|
2018-01-24 |
2021-03-11 |
Nanjing Legend Biotech Co., Ltd. |
Anti-cd47 antibodies that do not cause significant red blood cell agllutination
|
AU2019222644B2
(en)
|
2018-02-13 |
2021-04-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
CN110144009B
(zh)
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
BR112020017382A2
(pt)
|
2018-03-09 |
2021-01-26 |
Agenus Inc. |
anticorpos anti-cd73 e métodos de uso dos mesmos
|
AU2019233577A1
(en)
|
2018-03-13 |
2020-09-03 |
Ose Immunotherapeutics |
Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
|
WO2019179366A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-cd47 antibodies
|
BR112020018927A2
(pt)
|
2018-03-21 |
2021-01-05 |
ALX Oncology Inc. |
Anticorpos contra proteína alfa reguladora de sinal e métodos de uso
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
CN110305212A
(zh)
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
CN110386984B
(zh)
|
2018-04-17 |
2022-04-22 |
杭州尚健生物技术有限公司 |
结合cd47蛋白的融合蛋白及其应用
|
AU2019262218A1
(en)
|
2018-05-03 |
2020-12-10 |
Board Of Regents, The University Of Texas System |
Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
|
MX2020012137A
(es)
|
2018-05-14 |
2021-01-29 |
Gilead Sciences Inc |
Inhibidores de mcl-1.
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技(成都)有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
WO2019241732A1
(en)
|
2018-06-15 |
2019-12-19 |
Accurus Biosciences, Inc. |
Blocking antibodies against cd47 and methods of use thereof
|
JP2021529219A
(ja)
|
2018-07-05 |
2021-10-28 |
トリカン・バイオテクノロジー・カンパニー・リミテッドTrican Biotechnology Co., Ltd |
ヒト抗cd47抗体およびその使用
|
CA3104462C
(en)
|
2018-07-10 |
2023-12-19 |
Daiichi Sankyo Company, Limited |
Anti-sirp.alpha. antibody
|
JP7105359B2
(ja)
|
2018-07-13 |
2022-07-22 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2020019135A1
(zh)
|
2018-07-23 |
2020-01-30 |
中国科学院微生物研究所 |
一种抗cd47抗体及其应用
|
CN112805029A
(zh)
|
2018-08-13 |
2021-05-14 |
安驰肿瘤公司 |
治疗性cd47抗体
|
JP2021535743A
(ja)
|
2018-08-31 |
2021-12-23 |
南京聖和薬業股▲ふん▼有限公司Nanjing Sanhome Pharmaceutical Co., Ltd. |
抗cd47抗体及びその応用
|
WO2020068752A1
(en)
|
2018-09-27 |
2020-04-02 |
Celgene Corporation |
SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF
|
TWI721623B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
TWI721624B
(zh)
|
2018-10-31 |
2021-03-11 |
美商基利科學股份有限公司 |
經取代之6-氮雜苯并咪唑化合物
|
JP7371243B2
(ja)
|
2019-10-18 |
2023-10-30 |
フォーティ セブン, インコーポレイテッド |
骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法
|